Attached files
Exhibit 10.6
February 2, 2012
Ms. Vered Caplan
6 Sharabi street, Neve tzedek,
Tel-Aviv 65147, Israel
Dear Vered,
RE: DIRECTOR COMPENSATION AND EXPENSES
Orgenesis Inc. (the "COMPANY") would like to thank you for indicating your
willingness to serve as a director on the board of directors of the Company (the
"BOARD"). In connection therewith and in consideration for contributing your
expertise and network towards supporting the Company's efforts and service on
the Board, the Company will provide you with the following compensation:
1. The Company shall reimburse you for expenses that were approved in advance
by the Company and incurred by you in connection with your services as a
director, against valid invoices furnished to the Company.
2. (a) You will be provided with a Director Indemnification Agreement in
substantially the same form executed with the other directors of the
Company.
(b) The Company currently maintains Director's Liability Insurance, which
coverage will apply also to you and shall continue to maintain such
Director's Liability Insurance during your service with the Company
and thereafter until the completion of the statute of limitations on
any potential claim (or shall alternatively, following your service
with the Company shall obtain a run-off policy).
3. You will be paid a monthly fee of NIS 10,000 plus VAT, if applicable. All
payments shall be made against a valid tax invoice, to be provided by you
to the Company once a month and shall be paid by no later than ten days
following receipt of such invoice.
4. In the event the Company consummates one or more equity financings pursuant
to which it receives an aggregate of at least $2,000,000 while you are
still serving on the Board, then the Company shall pay you a one time bonus
of $100,000 plus VAT, if applicable.
5. You will receive, subject to the Company adopting a Share Option Plan, with
such terms and conditions as the Board may approve in its sole discretion
(the "PLAN") and subject to you signing the Company's standard form of
option agreement approved by the Board, in its sole discretion, stock-based
remuneration in the form of an option to purchase of up to 3,338,285 shares
of common stock of the Company (the "OPTIONS"). Any shares of common stock
issued pursuant to the Options will be subject to an escrow agreement
between you, the Company, and Clark Wilson LLP and will not be released
from escrow until two years from the closing date of the license agreement
between the Company's subsidiary, Orgenesis Ltd., and Tel Hashomer -
Medical Research, Infrastructure and Services Ltd. The Options shall be
granted under the Capital Gains Track of Section 102 of the Israeli Income
Tax Ordinance and shall have an exercise price of $0.001 per share.
6. By signing below you agree to keep any and all confidential information of
the Company and its subsidiaries and affiliates confidential and any and
all intellectual property developed by you while providing services to the
Company, shall be the exclusive property of the Company and you hereby
assign all rights thereto to the Company.
If the above is acceptable to you, we would appreciate if you would confirm
your acceptance to the arrangement specified hereinabove by signing where
indicated below.
Sincerely yours,
/s/ Vered Caplan
---------------------------
Orgenesis Inc.
Accepted and agreed:
/s/ Vered Caplan
---------------------------
Vered Capla